计算溶液所需的质量、体积或浓度。
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα , with an IC 50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity
In Vitro
PI3Kα-IN-4 (compound 10) inhibits PI3Kα, β, δ, and γ, with IC 50 s of 1.8, 271.0, 13.9, and 13.8 nM, respectively in kinase assays. PI3Kα-IN-4 inhibits PI3Kα, β, δ, and γ, with IC 50 s of 12.1,1393, 183, and >10000 nM, respectively in cell based assays. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
PI3Kα-IN-4 (compound 10) (30 mg/kg; p.o. once daily for 21 d) achieves the best efficacy, which could inhibit tumor growth by 73.0% in mice . PI3Kα-IN-4 (15-40 mg/kg; p.o. once daily for 30 d) dose dependently suppresses tumor growth by 62.5% (15 mg/kg), 86.0% (30 mg/kg) and 90.7% (40 mg/kg), respectively in mice . PI3Kα-IN-4 (15-40 mg/kg; p.o. once daily; 1-4 h) inhibits the phosphorylation of Akt in a dose- and time-dependent manner in vivo . PI3Kα-IN-4 shows high C max (mouse 22167, rat 2327 nM) and good bioavailability (mouse 59.4%, rat 46.9%) following oral administration (mouse 10, rat 3 mg/kg) . PI3Kα-IN-4 shows t 1/2 (mouse 0.99, rat 1.22 h) and low plasma clearance (mouse 4.16, rat 5.28 mL/min/kg) following intravenous injection (mouse 1, rat 1 mg/kg) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BT-474 subcutaneous xenograft mice Dosage: 30 mg/kg Administration: P.o. once daily for 21 days Result: Inhibited tumor growth by 73.0% and could be tolerated.
Form:Solid
IC50& Target:PI3Kα 1.8 nM (IC 50 )